These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

942 related items for PubMed ID: 15344210

  • 1. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2004 Aug 31; 45(4):676-82. PubMed ID: 15344210
    [Abstract] [Full Text] [Related]

  • 2. Early changes in urinary cross-linked N-terminal telopeptides of type I collagen level correlate with 1-year response of lumbar bone mineral density to alendronate in postmenopausal Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    J Bone Miner Metab; 2005 Aug 31; 23(3):238-42. PubMed ID: 15838627
    [Abstract] [Full Text] [Related]

  • 3. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Ichimura S, Uzawa M.
    Keio J Med; 2003 Jun 31; 52(2):113-9. PubMed ID: 12862363
    [Abstract] [Full Text] [Related]

  • 4. Effect of walking exercise on bone metabolism in postmenopausal women with osteopenia/osteoporosis.
    Yamazaki S, Ichimura S, Iwamoto J, Takeda T, Toyama Y.
    J Bone Miner Metab; 2004 Jun 31; 22(5):500-8. PubMed ID: 15316873
    [Abstract] [Full Text] [Related]

  • 5. Effect of whole-body vibration exercise on lumbar bone mineral density, bone turnover, and chronic back pain in post-menopausal osteoporotic women treated with alendronate.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Aging Clin Exp Res; 2005 Apr 31; 17(2):157-63. PubMed ID: 15977465
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the effect of alendronate on lumbar bone mineral density and bone turnover in men and postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Clin Rheumatol; 2007 Feb 31; 26(2):161-7. PubMed ID: 16565894
    [Abstract] [Full Text] [Related]

  • 7. Early changes in biochemical markers of bone turnover predict bone mineral density response to antiresorptive therapy in Korean postmenopausal women with osteoporosis.
    Kim SW, Park DJ, Park KS, Kim SY, Cho BY, Lee HK, Shin CS.
    Endocr J; 2005 Dec 31; 52(6):667-74. PubMed ID: 16410657
    [Abstract] [Full Text] [Related]

  • 8. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Dec 31; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 9. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
    Biermasz NR, Hamdy NA, Janssen YJ, Roelfsema F.
    J Clin Endocrinol Metab; 2001 Jul 31; 86(7):3079-85. PubMed ID: 11443170
    [Abstract] [Full Text] [Related]

  • 10. Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption, and chronic back pain in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Clin Rheumatol; 2004 Oct 31; 23(5):383-9. PubMed ID: 15278749
    [Abstract] [Full Text] [Related]

  • 11. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M, Zhang ZL, Liao EY, Chen DC, Liu J, Tao TZ, Wu W, Xia WB, Lu YJ, Sheng ZF, Lu CY, Meng GL, Xu L, Zhang WJ, Hu YY, Xu L.
    Menopause; 2013 Jan 31; 20(1):72-8. PubMed ID: 22968256
    [Abstract] [Full Text] [Related]

  • 12. Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: a 3-year follow-up study.
    Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H.
    J Bone Miner Metab; 2004 Jan 31; 22(5):462-8. PubMed ID: 15316867
    [Abstract] [Full Text] [Related]

  • 13. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2005 Dec 31; 46(6):750-8. PubMed ID: 16385649
    [Abstract] [Full Text] [Related]

  • 14. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 31; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 15. Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
    Iwamoto J, Uzawa M.
    Clin Rheumatol; 2016 Jan 31; 35(1):205-12. PubMed ID: 25367347
    [Abstract] [Full Text] [Related]

  • 16. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O, Yoshikata I, Kikuchi R, Nakayama M, Uchiyama Y, Hirahara F, Gorai I.
    J Bone Miner Res; 2000 Aug 31; 15(8):1537-44. PubMed ID: 10934652
    [Abstract] [Full Text] [Related]

  • 17. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group.
    J Bone Miner Res; 2002 Nov 31; 17(11):1988-96. PubMed ID: 12412806
    [Abstract] [Full Text] [Related]

  • 18. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 31; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 19. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E, Lyritis GP, Kosmidis C, Galanos A, Andypas G, Chorianopoulos K, Giagiosis A, Iliadou K, Karagianis A, Katsimichas K, Koskinas A, Matsouka K.
    Clin Rheumatol; 2005 Jun 31; 24(3):232-8. PubMed ID: 15647969
    [Abstract] [Full Text] [Related]

  • 20. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
    Takata S, Abbaspour A, Yonezu H, Yasui N.
    J Med Invest; 2007 Feb 31; 54(1-2):35-40. PubMed ID: 17380012
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.